Evidence map›Paper›PMID 41034297›Full record

ArticleScientific reports2025

Pulegone induced apoptotic and anti-proliferative potential in cervical cancer via P53, BAX and BCL2.

Tahir Maqbool, Faheem Hadi, Sadia Naz, Inamullah, Muhammad Abdul Basit Ashraf, Muhammad Rafiq, Rabia Rasool, Muhammad Atif, Awais Altaf, Tahir Muhammad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tahir MaqboolCentre of Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan. tahir.maqbool@imbb.uol.edu.pk.
Faheem HadiFaculty of Medicine and Allied Health Sciences, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Sadia NazDepartment of Allied Health Science, The University of Lahore, Lahore, Pakistan.
InamullahCentre of Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Muhammad Abdul Basit AshrafDepartment of Physiology, Faisalabad Medical University Faisalabad, Faisalabad, Pakistan.
Muhammad RafiqLahore School of Behavioral Sciences, The University of Lahore, Lahore, Pakistan.
Rabia RasoolDepartment of Emerging Allied Health Technologies, The university of Lahore, Lahore, Pakistan.
Muhammad AtifCentre of Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Awais AltafCentre of Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Tahir MuhammadDepartment of Anatomy and Cell Biology, New York Medical College, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is ranked the fourth most ocervical cancerurring gynecologic malignancy and thus becomes a serious point of concern in the world of cancer. The morbidity and mortality of cervical cancer is still high despite advancements in its prevention and treatment. The anticancer effects of pulegone in conjunction with conventional chemotherapy provide a better therapeutic approach. The present study was designed to assess the implications of putative in vitro anti-proliferative effects of pulegone against cervical cancer. HeLa, VERO, CaSKi and SiHa cells were cultured in complete DMEM media. MTT assay was performed to evaluate cell viability. p53 and annexin V was evaluated through ELISA for apoptosis. Immunocytochemistry was performed to determine cell death. Total protein content was determined by using Western blotting. The cytotoxicity of HeLa cells was dramatically increased with pulegone at a dose of 10 µM with no cytotoxic effect on VERO cells at all doses. Pulegone-treated HeLa cells showed an increasing degree of Annexin V staining. After pulegone treatment, fluorescent Hoechst 33,342 staining showed that nuclei were fragmented and condensed, a typical apoptotic morphology. Immunocytochemistry of P53 showed an increased apoptosis in Pulegone-treated cells compared to control and Cisplatin. Protein expression of BAX was increased and BCL2 decreased in pulegone treated cells. The present study portrayed that pulegone has potential anti-proliferative activities against cervical cancer cell lines with no toxic effect on normal cells. Thus, pulegone can be used as a potent therapeutic option either alone or when co-administered with traditional chemotherapy in the treatment of cervical cancer.

Indexed as

Apoptosisbcl-2-Associated X ProteinProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53Uterine Cervical NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalChlorocebus aethiopsFemaleHeLa CellsHumansVero CellsAntineoplastic AgentsBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanProto-Oncogene Proteins c-bcl-2TP53 protein, humanTumor Suppressor Protein p53Anti-proliferative effectsCervical cancerHeLa cellsPulegone

Identifiers

PMID41034297
PMCPMC12488903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.